NVST · Insider Trading
Envista Holdings Corporation Common stock, $0.01 par value per share
Every open-market purchase and sale reported by NVST officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-11-02 | Paul A Keel | Chairman and CEO | F | −54,197 | −$1.27M |
| 2026-08-27 | Stefan Nilsson | President, Nobel Biocare | F | −804 | −$22.09K |
| 2026-08-27 | Eric D. Hammes | Chief Financial Officer | F | −10,885 | −$299.01K |
| 2026-08-27 | Robert Befidi | President, Diagnostics | F | −5,147 | −$141.39K |
| 2026-08-27 | Veronica Acurio | President, Orthodontics | F | −7,710 | −$211.79K |
| 2026-08-24 | Mischa Reis | SVP, Strategy & Bus. Dev. | Sell | −8,000 | −$220.00K |
| 2026-08-20 | Eric D. Hammes | Chief Financial Officer | A | +47,970 deriv. | — |
| 2026-08-20 | Paul A Keel | Chief Executive Officer | A | +179,730 | — |
| 2026-05-27 | Paul A Keel | Chief Executive Officer | F | −12,811 | −$300.16K |
| 2026-05-21 | R Scott Huennekens | Director | A | +12,585 | — |
| 2026-05-21 | Daniel Raskas | Director | A | +9,330 | — |
| 2026-05-21 | James Andrew Pierce | Director | A | +9,330 | — |
| 2026-05-21 | Kieran Gallahue | Director | A | +9,330 | — |
| 2026-05-21 | Vivek Jain | Director | A | +9,330 | — |
| 2026-05-21 | Christine A Tsingos | Director | A | +9,330 | — |
| 2026-05-21 | Wendy Carruthers | Director | A | +9,330 | — |
| 2026-02-27 | Robert Befidi | President, Diagnostics | MIXED | +5,428 | −$64.42K |
| 2026-02-27 | Paul A Keel | Chief Executive Officer | MIXED | +36,830 | −$350.35K |
| 2026-02-27 | Faez C Kaabi | Chief Accounting Officer | MIXED | +8,556 | −$146.88K |
| 2026-02-27 | Mark E Nance | General Counsel | MIXED | +9,307 | −$99.66K |
| 2026-02-27 | Mischa Reis | SVP, Strategy & Bus. Dev. | MIXED | +2,939 | −$88.06K |
| 2026-02-27 | Stefan Nilsson | President, Nobel Biocare | MIXED | +7,423 | −$5.39K |
| 2026-02-27 | Veronica Acurio | President, Orthodontics | MIXED | +6,193 | −$41.78K |
| 2026-02-27 | Eric D. Hammes | Chief Financial Officer | MIXED | +14,010 | −$60.51K |
| 2026-02-11 | Mischa Reis | SVP, Strategy & Bus. Dev. | MIXED | — | −$123.33K |
| 2026-02-03 | Veronica Acurio | President, Orthodontics | A | +998 deriv. | — |
| 2026-02-03 | Faez C Kaabi | Chief Accounting Officer | A | +1,186 deriv. | — |
| 2026-02-03 | Mark E Nance | General Counsel | A | +2,006 deriv. | — |
| 2026-02-03 | Paul A Keel | Chief Executive Officer | A | +4,091 deriv. | — |
| 2026-02-03 | Eric D. Hammes | Chief Financial Officer | A | +1,119 deriv. | — |
| 2026-02-03 | Mischa Reis | SVP, Strategy & Bus. Dev. | A | +2,919 deriv. | — |
| 2026-02-03 | Robert Befidi | President, Diagnostics | A | +998 deriv. | — |
| 2025-11-04 | Paul A Keel | Chief Executive Officer | F | −54,097 | −$1.10M |
| 2025-08-27 | Mischa Reis | SVP, Strategy & Bus. Dev. | Sell | −15,000 | −$324.00K |
| 2025-08-27 | Veronica Acurio | President, Orthodontics | F | −5,422 | −$114.51K |
| 2025-08-27 | Stefan Nilsson | President, Nobel Biocare | F | −804 | −$16.98K |
| 2025-08-27 | Eric D. Hammes | Chief Financial Officer | F | −7,654 | −$161.65K |
| 2025-08-27 | Robert Befidi | President, Diagnostics | F | −3,454 | −$72.95K |
| 2025-07-16 | James Andrew Pierce | Director | A | +9,155 | — |
| 2025-06-12 | R Scott Huennekens | Director | A | +14,370 | — |
| 2025-06-12 | Barbara B. Hulit | Director | A | +10,450 | — |
| 2025-06-12 | Christine A Tsingos | Director | A | +10,450 | — |
| 2025-06-12 | Wendy Carruthers | Director | A | +10,450 | — |
| 2025-06-12 | Vivek Jain | Director | A | +10,450 | — |
| 2025-06-12 | Daniel Raskas | Director | A | +10,450 | — |
| 2025-06-12 | Kieran Gallahue | Director | A | +10,450 | — |
| 2025-05-27 | Paul A Keel | Chief Executive Officer | F | −12,787 | −$213.80K |
| 2025-02-27 | Mark E Nance | General Counsel | MIXED | +14,464 | −$76.26K |
| 2025-02-27 | Eric D. Hammes | Chief Financial Officer | A | +15,735 | — |
| 2025-02-27 | Robert Befidi | President, Diagnostics | MIXED | +9,167 | −$23.20K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Paul A Keel | Chairman and CEO | 497,107 | $12.85M |
| Eric D. Hammes | Chief Financial Officer | 99,913 | $2.58M |
| R Scott Huennekens | Director | 82,105 | $2.12M |
| Barbara B. Hulit | Director | 79,820 | $2.06M |
| Mark E Nance | General Counsel | 68,577 | $1.77M |
| Stefan Nilsson | President, Nobel Biocare | 61,560 | $1.59M |
| Wendy Carruthers | Director | 59,940 | $1.55M |
| Christine A Tsingos | Director | 59,930 | $1.55M |
| Faez C Kaabi | Chief Accounting Officer | 58,552 | $1.51M |
| Daniel Raskas | Director | 54,010 | $1.40M |
| Kieran Gallahue | Director | 54,010 | $1.40M |
| Vivek Jain | Director | 52,945 | $1.37M |
| Veronica Acurio | President, Orthodontics | 48,806 | $1.26M |
| Robert Befidi | President, Diagnostics | 45,785 | $1.18M |
| Mischa Reis | SVP, Strategy & Bus. Dev. | 27,321 | $705.97K |
| James Andrew Pierce | Director | 18,485 | $477.65K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the NVST quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.